Max Healthcare Institute Ltd Q4 FY2022 Concall Summary

Key Takeaways

• Omicron hit Q4, but recovery was swift: Occupancy fell to 60% in January as the wave disrupted doctors and elective work, yet averaged 68% for the quarter, and international revenue recovered to 90% of pre-COVID levels by March.
• A 2,800-bed expansion plan is now funded and underway: Four inorganic deals and four brownfield projects will add over 2,800 beds in five years, backed by a Rs. 3,700 crore capex plan funded entirely through internal accruals.
• Payor mix is the big ARPOB lever: Management sees a step-change opportunity from shifting the remaining ~30% institutional beds (at 40-45% lower rates) toward cash-and-insurance patients, targeting a reduction in institutional mix from 30-31% to ~15% over two years.
• Diagnostics strategy leans on the hospital brand: MaxLab grew non-COVID revenue 85% YoY, and management argues its hospital-backed credibility gives it a right to survive an eventual industry shakeout, though it will use stock, not cash, for any lab acquisitions.
• What to watch next quarter: Whether the institutional mix reduction accelerates now that CGHS OPD has been stopped, the pace of Nanavati’s personnel cost normalization, and any inorganic deal closure as valuations turn sensible.

Omicron Disruption & Q4 Recovery

• January was the trough: Widespread Omicron infections sidelined doctors and disrupted specialties in the first half, pulling occupancy to 60% and lowering OPD footfalls; the second half rebounded sharply.
• COVID beds dragged margins: An average 7% of beds were used for COVID patients, whose lower ARPOB and high PPE consumption, combined with lower overall occupancy, pushed the institutional business mix higher and lifted direct costs 140 bps QoQ.
• OPD footfalls also reflect deliberate pruning: Beyond COVID disruption, Q3 saw a deliberate OPD decline because the company dis-empanelled from state schemes like DGHS that generated high OPD visits but low IPD conversion; from April onward, numbers are normalizing.
• International business is nearly back: Medical tourism recovered to 90% of pre-COVID levels in March 2022 and is expected to exceed 100% soon, adding a high-ARPOB revenue stream.

Soi: "the two drivers of ARPOB or three drivers, one will be a clinical mix, which is incremental, it's not exponential, I see a major push coming from payor mix change... And the third is, the international business coming back"

The 2,800-Bed Expansion Plan

• Inorganic pipeline delivered four transactions in FY22: Acquisition of a stake in Eqova Healthcare (400 beds, East Delhi), an O&M agreement for a 300-bed under-construction hospital in Dwarka, exclusive rights to a 500-bed upcoming hospital in Saket, and two Gurugram land parcels totaling 11 acres with capacity for over 1,000 beds.
• Brownfield projects add another 1,300 beds: Expansions are ongoing at Shalimar Bagh, Saket, and Nanavati; collectively, the inorganic and brownfield pipelines target over 2,800 beds within five years.
• Capex is fully internally funded: The Rs. 3,700 crore expected spend will be met through internal accruals alone, with no external financing required.
• Brownfield urgency is real: Existing hospitals have run out of space: emergency waiting times stretch from 6 hours to 1.5 days for a bed of choice, and management has been moved outside because offices were cannibalized for clinical use.

Payor Mix & ARPOB

• Institutional bed share is down but still material: The proportion fell from 37% to 30-31% through dis-empanelment of select institutional accounts, a process that could have moved faster absent COVID-driven occupancy swings.
• The target is ~15% within two years: Management expects the institutional/lower-realisation bed proportion to halve from current levels, describing the ARPOB uplift as a mathematical exercise: shifting a bed from institutional to cash-and-insurance yields 40-45% more revenue.
• CGHS OPD was stopped entirely: The company exited CGHS OPD business at the Rs. 156 per consult rate, a move that made front-page news; CGHS payment delays are industry-wide as the system transitions to the National Health Authority.
• Annual price increases contribute 2-3%: TPA agreements are revised every 18-24 months; major TPAs were revised last year, so this year’s increase is lower, but the yearly ritual adds a steady tailwind.
• Clinical mix improvement is incremental, not step-change: The case mix is already superior; further gains will be gradual, unlike the payor mix opportunity which management frames as a discrete, large shift.

Soi: "The minute we are moving institutional beds down and replacing with CTI that gives me 40%, 45% more revenue. That means my ARPOB on those beds is 45% higher, it is a mathematical exercise."

Nanavati Turnaround

• Personnel cost is the main drag: Staff costs at Nanavati still run near 30% of revenue versus the 20-23% norm elsewhere in the network; a first round of VRS has brought costs down, and subsequent rounds are ongoing.
• Phase one expansion adds 329 beds without demolition: As beds come online, the existing workforce gets spread over a larger base, which management expects will normalize the cost ratio over the course of the year.
• Phase two will demolish ~150 beds of the original structure: After both phases, Nanavati reaches 760 census beds, with the full ramp-up providing the scale needed to bring margins closer to network levels.

Diagnostics: MaxLab & Max@Home

• MaxLab delivered strong FY22 growth: Revenue rose 53% YoY, with non-COVID revenue up 85% YoY on a smaller base; 60 channel partners were added in Q4, taking active clients to 760 across 25 cities.
• The hospital brand is the competitive moat: Management argues that clinicians rest their practice on MaxLab reports, and a report bearing the Max hospital brand cannot be discounted the way a standalone lab’s can; this credibility is the reason to survive an eventual industry shakeout.
• Diagnostics M&A will use stock, not cash: Management believes both margins and multiples in the lab sector will be under stress and that the sector is highly valued; any acquisition would be ROCE-accretive and done with equity, focused on North and West geographies.
• No big-bang organic leap in diagnostics: The strategy is to move up the value chain toward high-end and one-off tests, with no single initiative expected to 3x the business in the near term.
• Max@Home added ~70 people in Q4: The home-care team continues to scale alongside the lab network.

Soi: "All of what Max does is predicated on the efficacy and the efficiency of our laboratories -- that is what all our senior clinicians and all everyone sort of rest their entire practice on. ... you cannot discount or discard a MaxLab report it is coming from hospital, right?"

Inorganic Growth & Capital Allocation

• Valuations are turning sensible: Management sees plenty of PE-owned hospital chains and standalone hospitals up for sale, and notes that the hectic valuation periods are giving way to more serious discussions.
• Geographic expansion will be opportunistic and M&A-led: Beyond Delhi NCR, the company will look at other geographies through acquisitions rather than greenfield buildouts; if an opportunity arises in Bengaluru, it would pursue it.
• Digital marketing spend is rising structurally: The digital marketing budget is increasing ~60% for the next year, described as a permanent line-item shift to a higher allocation for all times to come.

Soi: "There are plenty of inorganic growth opportunities available because there are lots of PE-owned hospital chains up for sale, there are lots of standalone ones up for sale. ... You are seeing some sensibility around valuations. Those hectic periods are -- so it is getting back to serious business."

Defensive Sector Dynamics

• Input cost inflation is largely a pass-through: Medicine costs are passed to patients, with the company only earning a margin on them; there has never been an output price cap, only input price caps on items like stents and implants.
• Management calls the sector counter-cyclical and anti-inflationary: The medical sector is described as insulated from inflation globally, and in India it is "offensive" rather than merely defensive because of huge under-penetration.

Soi: "...if there is one sector, which is counter cyclical, is anti-inflationary, is insulated from inflation is perhaps the medical sector. I mean, not India globally, not only us I think that is the nature of the business. It is a defensive. In India it is so offensive, simply because of the huge under penetration."

Guidance & Commitments

Key Metrics